← Leaderboards
Michael Hemann
Massachusetts Institute Of Technology
$6,314,382
Attributed
$9,891,271
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,891,271 · 8
By mechanism
R01$7,185,872 · 4
U01$1,302,677 · 1
P30$994,596 · 2
R21$408,126 · 1
Top collaborators
- Christopher B Burge5 shared
- Phillip A Sharp5 shared
- Michael B Yaffe5 shared
- Andrew A Lane2 shared
- Scott R Manalis2 shared
- Tuomas Tammela2 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Joanne Stubbe$16,578,287
- Scott R Manalis$18,853,425
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponsePharmaceutical PreparationsTumorMalignant NeoplasmsMouse ModelCancer TherapyCellsResistanceDrug ResistanceResearch PersonnelChemotherapySuccessTechnologyRelapseIn VivoPathway InteractionsBaseMutationGenesProgramsGeneticAntineoplastic AgentsHeterogeneityNeoplastic Cell
Grant awards (31)
Investigating hypoxia as a determinant of malignant fates in pancreas cancer$695,122
R01 · FY2025 · CA
Targeting minimal residual disease in AML by using single-cell morphological and biophysical analysis with deep learning$655,219
U01 · FY2025 · CA
Investigating hypoxia as a determinant of malignant fates in pancreas cancer$714,122
R01 · FY2024 · CA
Targeting minimal residual disease in AML by using single-cell morphological and biophysical analysis with deep learning$647,458
U01 · FY2024 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies$525,766
R01 · FY2023 · CA
Identifying and targeting evolutionary trajectories in cancer$335,673
R01 · FY2023 · CA · contact PI
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies$536,497
R01 · FY2022 · CA
Identifying and targeting evolutionary trajectories in cancer$335,090
R01 · FY2022 · CA · contact PI
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies$536,497
R01 · FY2021 · CA
Identifying and targeting evolutionary trajectories in cancer$341,350
R01 · FY2021 · CA · contact PI
Dissecting the mechanism of cyclophosphamide-enhanced antibody efficacy$185,238
R21 · FY2021 · AI · contact PI
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies$536,497
R01 · FY2020 · CA
Identifying and targeting evolutionary trajectories in cancer$340,788
R01 · FY2020 · CA · contact PI
Dissecting the mechanism of cyclophosphamide-enhanced antibody efficacy$222,888
R21 · FY2020 · AI · contact PI
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies$536,497
R01 · FY2019 · CA
Identifying and targeting evolutionary trajectories in cancer$340,243
R01 · FY2019 · CA · contact PI
Genomics$176,424
P30 · FY2019 · CA · contact PI
Genomics$113,872
P30 · FY2018 · CA · contact PI
Genomics$113,871
P30 · FY2017 · CA · contact PI
Genomics$113,872
P30 · FY2016 · CA · contact PI
Genomics$169,435
P30 · FY2015 · CA · contact PI
Applied Therapeutics & Whole Animal Imaging$44,001
P30 · FY2014 · CA · contact PI
Applied Therapeutics & Whole Animal Imaging$124,711
P30 · FY2013 · CA · contact PI
Applied Therapeutics & Whole Animal Imaging$45,351
P30 · FY2012 · CA · contact PI
Identifying determinants of chemotherapeutic response in vivo$273,789
R01 · FY2011 · CA · contact PI
Applied Therapeutics & Whole Animal Imaging$45,346
P30 · FY2011 · CA · contact PI
Identifying determinants of chemotherapeutic response in vivo$282,403
R01 · FY2010 · CA · contact PI
Applied Therapeutics & Whole Animal Imaging$47,713
P30 · FY2010 · CA · contact PI
Identifying determinants of chemotherapeutic response in vivo$282,545
R01 · FY2009 · CA · contact PI
Identifying determinants of chemotherapeutic response in vivo$287,280
R01 · FY2008 · CA · contact PI
Identifying determinants of chemotherapeutic response in vivo$285,713
R01 · FY2007 · CA · contact PI